Halozyme Q2 Revenue Surges 48% to $481M, Raises 2026 Guidance on ENHANZE Momentum
HALO sits 47% above its 52-week low of $61.225.
Summary
Halozyme delivered a blowout Q2, with total revenue up 48% YoY to $481M and royalty revenue up 50% to $308M, both records. Adjusted EBITDA grew 46% to $329M. The company raised full-year 2026 guidance across all metrics, now projecting total revenue of $1.835-$1.910B (31-37% growth) and non-GAAP diluted EPS of $8.65-$9.00 (108-117% growth). Five new ENHANZE and Hypercon collaborations signed YTD already exceed the full-year goal of three, signaling accelerating partner adoption. The company repurchased $332.8M in shares during Q2 at an average price of $69.30, well below the current $90.0 level, adding to shareholder value. This follows a strong Q1 beat and a new $1B buyback program announced in May. The stock is trading near a 52-week high, reflecting sustained execution and pipeline expansion.
At the time of this announcement, HALO was trading at $90.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $61.23 to $86.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.